Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone

MeSH terms

• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use*
• Child
• Child, Preschool
• Cyclophosphamide / adverse effects
• Cyclophosphamide / therapeutic use*
• Cytarabine / therapeutic use*
• Drug Evaluation
• Drug Resistance
• Drug Therapy, Combination
• Humans
• Infant
• Inosine / adverse effects
• Inosine / analogs & derivatives*
• Inosine / therapeutic use
• Mercaptopurine / adverse effects
• Mercaptopurine / therapeutic use*
• Neoplasm Metastasis
• Neuroblastoma / drug therapy*
• Remission, Spontaneous
• Sulfides / adverse effects
• Sulfides / therapeutic use
• Vincristine / adverse effects
• Vincristine / therapeutic use*